These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 25262921

  • 1. Minor histocompatibility antigens: past, present, and future.
    Spierings E.
    Tissue Antigens; 2014 Oct; 84(4):374-60. PubMed ID: 25262921
    [Abstract] [Full Text] [Related]

  • 2. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
    Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, Oudshoorn M, Loiseau P, Dolstra H, Markiewicz M, Leffell MS, Pereira N, Kircher B, Turpeinen H, Eliaou JF, Gervais T, Laurin D, Enczmann J, Martinetti M, Thomson J, Oguz F, Santarone S, Partanen J, Siekiera U, Alessandrino EP, Kalayoglu S, Brand R, Goulmy E.
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
    [Abstract] [Full Text] [Related]

  • 3. Minor histocompatibility antigen typing by DNA sequencing for clinical practice in hematopoietic stem-cell transplantation.
    Spierings E, Goulmy E.
    Methods Mol Biol; 2012 Aug; 882():509-30. PubMed ID: 22665253
    [Abstract] [Full Text] [Related]

  • 4. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M, Bartsch K, Tschiedel S, Niederwieser D.
    Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
    [Abstract] [Full Text] [Related]

  • 5. Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation.
    Fuchs KJ, Falkenburg JHF, Griffioen M.
    Best Pract Res Clin Haematol; 2024 Jun; 37(2):101555. PubMed ID: 39098803
    [Abstract] [Full Text] [Related]

  • 6. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B, Kruisselbrink AB, Frederik Falkenburg JH, Jedema I.
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [Abstract] [Full Text] [Related]

  • 7. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S, Nijmeijer BA, van Schie ML, Salvatori DC, Maas S, Griffioen M, Falkenburg JH.
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [Abstract] [Full Text] [Related]

  • 8. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
    Laurin D, Hannani D, Pernollet M, Moine A, Plumas J, Bensa JC, Cahn JY, Garban F.
    Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Minor histocompatibility antigens: targets for tumour therapy and transplant tolerance.
    Spierings E.
    Int J Immunogenet; 2008 Aug; 35(4-5):363-6. PubMed ID: 18976439
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The relevance of minor histocompatibility antigens in solid organ transplantation.
    Dierselhuis M, Goulmy E.
    Curr Opin Organ Transplant; 2009 Aug; 14(4):419-25. PubMed ID: 19444105
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P, Jedema I, van Loenen MM, de Boer R, van Egmond HM, Hagedoorn RS, Hoogstaten C, Veld SAJ, Hageman L, van Liempt PAG, Zwaginga JJ, Meij P, Veelken H, Falkenburg JHF, Heemskerk MHM.
    Front Immunol; 2020 Aug; 11():1804. PubMed ID: 32973756
    [Abstract] [Full Text] [Related]

  • 17. [Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].
    Tanaka J.
    Nihon Rinsho; 2003 Sep; 61(9):1512-9. PubMed ID: 14515717
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation.
    Mutis T.
    Int J Hematol; 2003 Oct; 78(3):208-12. PubMed ID: 14604278
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.